TrialDiabetes care2011

Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes.

Gary E Meininger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.